page 1
page 2
page 3
page 4
page 5
page 6
page 7
page 8
page 9
page 10
page 11
page 12
page 13
page 14
page 15
page 16
page 17
page 18
page 19
page 20
page 21
page 22
page 23
page 24
page 25
page 26
page 27
page 28
page 29
page 30
page 31
page 32
page 33
page 34
page 35
page 36
page 37
page 38
page 39
page 40
page 41
page 42
page 43
page 44
page 45
page 46
page 47
page 48
page 49
page 50
page 51
page 52
page 53
page 54
page 55
page 56
page 57
page 58
page 59
page 60
page 61
page 62
page 63
page 64
page 65
page 66
page 67
page 68
page 69
page 70
page 71
page 72
page 73
page 74
page 75
page 76
page 77
page 78
page 79
page 80
page 81
page 82
page 83
page 84
page 85
page 86
page 87
page 88
page 89
page 90
page 91
page 92
page 93
page 94
page 95
page 96
page 97
page 98
page 99
page 100
page 101
page 102
page 103
page 104
page 105
page 106
page 107
page 108
page 109
page 110
page 111
page 112
page 113
page 114
page 115
page 116
page 117
page 118
page 119
page 120
page 121
page 122
page 123
page 124
page 125
page 126
page 127
page 128
page 129
page 130
page 131
page 132
page 133
page 134
page 135
page 136
page 137
page 138
page 139
page 140
page 141
page 142
page 143
page 144
page 145
page 146
page 147
page 148
page 149
page 150
page 151
page 152
page 153
page 154
page 155
page 156
page 157
page 158
page 159
page 160
page 161
page 162
page 163
page 164
page 165
page 166
page 167
page 168
page 169
page 170
page 171
page 172
page 173
page 174
page 175
page 176
page 177
page 178
page 179
page 180
page 181
page 182
page 183
page 184
page 185
page 186

UKINNOVATION UK93 UK Trade & Investment As the UK government's inward investment agency, it's our responsibility to understand the UK's strengths and to encourage investment wherever opportuni-ties exist. This means that we can help your company research emerging opportunities and get a new opera-tion up and running as quickly as possible. Our services include: » Impartial advice on where and how to set up business in the UK » In- depth tailored information, including advice on R& D, tax, human capital and visas » Introductions to professional advisers and key contacts » Access to lists of professional service organisations that can support your move to the UK » Access to life- science specialists who have a strong background in the sector » Practical help, including visits to suitable locations, finding business partners and accessing financial incentives » Investment aftercare » Access to UK government to voice views on business regulation and policy. Take advantage of these services and you too could be part of the UK life- sciences success story. For more information, visit: www. uktradeinvest. gov. uk UK life- sciences companies are pioneers in future growth areas such as regenerative and stratified medicine, which will help meet future challenges such as an ageing popu-lation and obesity, and help cancer treatments be more effective. The UK is home to both multinational pharmaceutical giants and to small innovative life- science companies. Five of the world's best- selling pharmaceuticals were developed in the UK, the UK medical biotechnology sec-tor leads Europe in the number of drugs in all stages of clinical development, and more than one third of Europe's bio- pharmaceutical clinical trials take place in the UK's various advanced research facilities. The UK's medical technology sector is also growing rap-idly, with the largest share in Europe at just over 2,000 companies, the majority of which are SMEs. A major con-tributor to the UK's success in life- sciences is the strength of its skills base. According to OECD statistics, the UK, which has four of the world's top 10 universities, has the highest number of life sciences degree- level graduates annually in Europe. Life- Sciences UKTI

94INNOVATION UKINNOVATION Almirall In January 2008, Spanish drug manufacturer Almi-rall opened up an office near London, expanding its European presence. " It had been our goal to move into the UK mar-ket since we decided to expand internationally," says Carlos Gallardo, General Manager of Almirall in the UK and Ireland. " Happily, we are doing even better than anticipated." Almirall received invaluable assistance from UK Trade & Investment ( UKTI) when planning its move. " UKTI was instrumental in quickly getting us up to speed on the UK market," recalls Gallardo. " Its advisers gave us information on the local markets for dermatological and respiratory products and also put us in touch with government contacts who helped answer questions on local regulations. From beginning to end, setting up in the UK was a smooth process." For more information, visit: www. almirall. com The UK's research environment is also world class, with the country ranked as the best performer in the G8 lead-ing economies per unit of R& D spend. UK researchers are responsible for 9% of the world's scientific papers, producing 16 research papers per US$ 1m of research funding, compared to 9.2 in the USA and 3.6 in Japan. It is therefore no surprise that UK scientists have won over 70 Nobel Prizes. As a result, the UK is recognised across the world as a hotbed of activity throughout the life- sciences market - something which has attracted high levels of foreign direct investment. Recent examples include US pharma-ceuticals giant Pfizer's announcement that it is grow-ing its presence in Cambridge, focused on Regenerative Medicine Research, and United Therapeutics' decision to expand its European headquarters in Surrey, a move likely to generate significant job creation over the next few years. Given the UK's world- beating infrastructure, investor-friendly regulatory and IP environment and its potential as a springboard to mainland Europe and beyond, such high- quality investment looks set to continue long into the future. Xiangxue Pharmaceuticals In 2007, Chinese pharmaceutical company Xiangxue set up a research centre in Cambridge to investigate traditional Eastern medicines. " We looked to the UK because of its reputation as a leader in pharmaceutical research," states Frank Wu, CEO of XiangCam, Xiangxue's UK branch. " We wanted to take advantage of its world- class research institutions, and Cambridge, with its top- rate facili-ties, seemed the natural location." Before establishing its operations in the UK, Xiangxue worked closely with UK Trade & Investment ( UKTI), which provided the company with information about the local bio- medical research community, invited it to networking events and pointed the firm in the direc-tion of technology and legal specialists. " Without the help we got from organisations like UKTI, we would not have been as successful," says Wu. " We can turn to them for assistance at any time." Life- Sciences UKTI